OBJECTIVE -To assess the relationship between annual fills for antidiabetes medications, ACE inhibitors, angiotensin II receptor blockers (ARBs), and lipid-lowering agents on hospitalization and Medicare spending for beneficiaries with diabetes.
A
pproximately 25% of Medicare beneficiaries have diabetes (1) . In 2002, the average beneficiary with diabetes spent $15,292 on medical services including $2,349 for prescription medications (1) . The economic burden of diabetes is huge-$27 billion in 2007 (2) rising to possibly $190 billion by 2020 (3) .
Recent studies suggest that better medication management for older individuals with diabetes not only improves health (4) and reduces mortality (5) , but also has the potential to reduce future medical care costs (6) and may be cost saving to the Medicare program (4 -5, 7-9) .
In this article, we examine annual We assessed the effect of prescription fill rates for users of each drug class on the risk of hospitalization, total annual hospital days, and spending on Medicare services measured in constant 2006 dollars, using the Consumer Price Index (12) . Covariates included an extensive list of demographic, socioeconomic, and health status indicators (see Table A1 in the online appendix available at http://care.diabetesjournals.org/ cgi/content/full/dc08-1311/DC1).
We estimated seven regression models, one per drug class, for each of the three dependent variables using personyear as the unit of analysis and the full set of covariates listed in the online appendix. Because the study subjects frequently used medications in two or more drug classes, we included fill rates for all seven drug classes in each equation. This procedure assured that the parameter coefficient on prescription fills for the subset of users of a particular drug class was conditioned on utilization of the other medication classes.
We used logistic regression for the hospitalization models and Poisson regression for the hospital day equations. For the Medicare spending models, we used a generalized linear equation with a
␥ distribution and log link to approximate the skewed distribution of Medicare expenditures (13) . All models were estimated in Stata (Release 9) with a robust cluster command to correct standard errors for repeated measures among subjects observed in multiple years. Results are reported as conditional marginal probabilities (hospitalization) or conditional marginal effects (dy/dx) of a unit change in prescription fills on the change in the dependent variable (hospital days and Medicare spending), with all other variables held at their mean values.
RESULTS -Almost one-third (30%) of the sample was hospitalized each year with rates ranging from 27.4% for users of older antidiabetes medications to 42.9% for insulin users ( Table 1 ). The mean number of inpatient days varied in a similar fashion. Mean annual Medicare spending ranged between 8,565 USD (older oral antidiabetes medication users) and 16,950 USD (insulin users).
User rates varied widely across the seven drug classes. Annual prevalence of older oral antidiabetes drug use was 47.1% compared with 13.3% for newer agents. Insulin use was infrequent (6.1%). The highest average annual fill rate was for older oral antidiabetes drugs (8.3), with annual fills hovering around 6 for the other classes.
The regression results are summarized in Table 1 . Overall, we found a consistent inverse relationship between prescription fill rates and the three dependent variables for older oral antidiabetes agents, ACE inhibitors, ARBs, and statins. The marginal effects of prescription fills for these four classes were negative and statistically significant in every case. Each additional prescription fill by users of older oral antidiabetes agents reduced hospitalization risk by 0.3%, reduced the number of hospital days by 0.04 days, and reduced Medicare spending by $71. Each added fill for ARB users reduced hospitalization risk by 1.3%, reduced the number of hospital days by 0.12 days, and reduced Medicare spending by $159. Similar results were seen for the other two drug classes.
The hospital effects may appear to be small, but with an average Medicare cost of $952 per inpatient day in 2006 (14) , the results translate into hospital cost offsets ranging from $38 per prescription for older oral antidiabetes agents to $114 for ARBs. For three of the drug classes, estimated Medicare savings exceeded the cost 
